Physician profile
Abbas Raza
NPI 1710391958
$1,149.94
in general payments reported to CMS, 2019-2025
14 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $56.64 · 2021: $348 · 2022: $258 · 2023: $126 · 2024: $86.20 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $294.63 | 2020-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $227.90 | 2023-2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $184.26 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $152.90 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $94.99 | 2019 | |
| Calliditas Therapeutics US INC. | $37.94 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $31.86 | 2024 | Jynarque |
| Biomerieux INC | $24.60 | 2019 | |
| Ardelyx, INC. | $22.24 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $17.10 | 2025 | |
| Novo Nordisk INC | $17.06 | 2025 | Ozempic |
| Akebia Therapeutics INC | $14.98 | 2020 | |
| Amgen INC. | $14.97 | 2021 | |
| Fresenius USA Marketing, INC. | $14.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.